Reata Pharmaceuticals, Inc.
RETANASDAQHealthcare
$172.36
+$0.04(+0.02%)
Market Cap$6.6B
P/E Ratio—
52W High$172.46
52W Low$21.83
Reata Pharmaceuticals, Inc.（RETA）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · RETA · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.22M | $11.49M | $9.02M | $26.52M | $53.59M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $124.40M | $0.00M |
| Gross Profit | $2.22M | $11.49M | $9.02M | ($97.88M) | $53.59M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | -369.13% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $169.84M | $155.99M | $159.08M | $128.11M | $97.29M |
| G&A Expenses | $109.28M | $99.00M | $75.13M | $58.30M | $32.75M |
| Total Operating Expenses | $280.25M | $256.20M | $235.34M | $187.34M | $130.47M |
| Operating Income | ($270.15M) | ($244.71M) | ($226.32M) | ($285.22M) | ($76.88M) |
| Operating Margin %(computed) | — | — | — | — | -143.46% |
| Interest Income | $5.99M | $0.18M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $41.77M | $53.25M | $36.78M | $11.20M | $6.18M |
| Income Before Tax | ($311.93M) | ($297.84M) | ($270.24M) | ($290.16M) | ($80.52M) |
| Income Tax Expense | ($0.03M) | ($0.45M) | ($22.49M) | $0.01M | $0.03M |
| Net Income | ($311.90M) | ($297.39M) | ($247.75M) | ($290.17M) | ($80.55M) |
| Net Margin %(computed) | — | — | — | — | -150.30% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-8.59 | $-8.19 | $-7.35 | $-9.54 | $-2.91 |
| Wtd Avg Shares | 36.32M | 36.32M | 33.71M | 30.41M | 27.70M |
| EBITDA | ($269.02M) | ($243.50M) | ($232.32M) | ($278.03M) | ($73.91M) |
| EBITDA Margin %(computed) | — | — | — | — | -137.93% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · USD · M
深入了解Reata Pharmaceuticals, Inc.
关于Reata Pharmaceuticals, Inc.（RETA）损益表
Reata Pharmaceuticals, Inc.（RETA）损益表数据来源于SEC Form 10-K及10-Q申报文件。2022财年，RETA实现营收$0.00B，毛利润$0.00B（毛利率100.00%），净利润($0.31B)（净利率-14074.95%）。
常见问题
RETA · 4 问Reata Pharmaceuticals, Inc.（RETA）2022财年营收为$0.00B，同比down80.7%。
RETA revenueRETA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09